Daniel Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daniel Park has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- David R. Thickett
English Heritage, Rangers House, London SE10 8QX, UK
1 shared publication - Derek Alderson
University Department of Surgery, Queen Elizabeth Hospital , Birmingham B15 2TH
1 shared publication - Dipesh Mistry
Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK
1 shared publication - Fang Gao Smith
Department of Inflammation and Ageing, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham, UK
1 shared publication - Gavin D. Perkins
Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK
1 shared publication - Matthew W. Cooke
Warwick Medical School, University of Warwick, Coventry, UK
1 shared publication
Latest Publications
- Open Access
- 15 March 2011
- Published by Springer Nature in Trials
- Vol. 12 (1) , 1-6
The Beta Agonist Lung Injury TrIal (BALTI) - prevention trial protocol
Acute lung injury complicates approximately 25-30% of subjects undergoing oesophagectomy. Experimental studies suggest that treatment with beta agonists may prevent the development of acute lung injury by decreasing inflammatory cell infiltration, activation and inflammatory cytokine release, enhancing basal alveolar fluid clearance and improving alveolar capillary barrier function. The Beta Agonist Lung Injury TrIal (prevention) is a multi-centre, randomised, double blind, placebo-controlled trial. The aim of the trial is to determine in patients undergoing elective transthoracic oesphagectomy, if treatment with inhaled salmeterol 100 mcg twice daily started at induction of anaesthesia and continued for 72 hours thereafter compared to placebo affect the incidence of early acute lung injury and other clinical, resource and patient focused outcomes. The primary outcome will be the development of acute lung injury within 72 hours of oesophagectomy. The trial secondary outcomes are the development of acute lung injury during the first 28 days post operatively; PaO2: FiO2 ratio; the number of ventilator and organ failure free days, 28 and 90 day survival; health related quality of life and resource utilisation. The study aims to recruit 360 patients from 10 UK centres. Current Controlled Trials ISRCTN47481946
- 15 March 2011
- Published by Springer Nature in Trials
- Vol. 12 (1) , 1-6
Open AccessThe Beta Agonist Lung Injury TrIal (BALTI) - prevention trial protocol
Acute lung injury complicates approximately 25-30% of subjects undergoing oesophagectomy. Experimental studies suggest that treatment with beta agonists may prevent the development of acute lung injury by decreasing inflammatory cell infiltration, activation and inflammatory cytokine release, enhancing basal alveolar fluid clearance and improving alveolar capillary barrier function. The Beta Agonist Lung Injury TrIal (prevention) is a multi-centre, randomised, double blind, placebo-controlled trial. The aim of the trial is to determine in patients undergoing elective transthoracic oesphagectomy, if treatment with inhaled salmeterol 100 mcg twice daily started at induction of anaesthesia and continued for 72 hours thereafter compared to placebo affect the incidence of early acute lung injury and other clinical, resource and patient focused outcomes. The primary outcome will be the development of acute lung injury within 72 hours of oesophagectomy. The trial secondary outcomes are the development of acute lung injury during the first 28 days post operatively; PaO2: FiO2 ratio; the number of ventilator and organ failure free days, 28 and 90 day survival; health related quality of life and resource utilisation. The study aims to recruit 360 patients from 10 UK centres. Current Controlled Trials ISRCTN47481946